HomeEVT • FRA
add
Evotec SE
Previous close
€5.77
Day range
€5.77 - €6.00
Year range
€5.12 - €23.25
Market cap
1.02B EUR
Avg Volume
7.29K
P/E ratio
-
Dividend yield
-
Primary exchange
ETR
In the news
Financials
Income Statement
Revenue
Net income
(EUR) | Jun 2024info | Y/Y change |
---|---|---|
Revenue | 182.12M | 6.96% |
Operating expense | 51.89M | -33.04% |
Net income | -94.93M | -535.89% |
Net profit margin | -52.13 | -494.41% |
Earnings per share | -0.18 | -361.25% |
EBITDA | -11.75M | -33.60% |
Effective tax rate | 9.12% | — |
Balance Sheet
Total assets
Total liabilities
(EUR) | Jun 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 298.87M | -51.86% |
Total assets | 2.00B | -13.14% |
Total liabilities | 987.43M | -12.38% |
Total equity | 1.01B | — |
Shares outstanding | 177.30M | — |
Price to book | 1.01 | — |
Return on assets | -4.30% | — |
Return on capital | -5.61% | — |
Cash Flow
Net change in cash
(EUR) | Jun 2024info | Y/Y change |
---|---|---|
Net income | -94.93M | -535.89% |
Cash from operations | -50.42M | -539.86% |
Cash from investing | -31.28M | -179.43% |
Cash from financing | -119.04M | -1,326.96% |
Net change in cash | -206.43M | -540.82% |
Free cash flow | -31.66M | — |
About
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Founded
1993
Website
Employees
5,022